Stay updated on Biosimilar Ustekinumab vs Stelara Clinical Trial
Sign up to get notified when there's something new on the Biosimilar Ustekinumab vs Stelara Clinical Trial page.

Latest updates to the Biosimilar Ustekinumab vs Stelara Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer now shows revision v3.8.1 instead of v3.8.0; the study details remain unchanged.SummaryDifference0.1%

- Check8 days agoChange DetectedThe page now presents the completed Phase 3 study of biosimilar ustekinumab versus Stelara for moderate-to-severe plaque psoriasis, including its eligibility criteria, locations, treatment arms, outcome measures, and publication details.SummaryDifference49%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide notice announces that NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision label advanced from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site footer revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Biosimilar Ustekinumab vs Stelara Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biosimilar Ustekinumab vs Stelara Clinical Trial page.